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Abstract In the last 5 years, many efforts have been
conductedsearchingpotentandselectivehumanA3 adenosine
antagonists. In this field several different classes of com-
pounds, possessing very good affinity (nM range) and with a
broad range of selectivity, have been proposed. Recently, our
group synthesized a new series of pyrazolo-triazolo-pyrimi-
dines bearing different substitutions at the N
5 and N
8
positions, which have been described as highly potent and
selective human A3 adenosine receptor antagonists. The
present review summarizes available data and provides an
overview of the structure–activity relationships found for this
class of human A3 adenosine receptor antagonists.
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Abbreviations
CGS15943 (9-chloro-2-(2-furanyl)[1,2,4]triazolo[1,5-c]
quinazolin-5-amine)
8FB-PTP 5-amino-8-(4-fluorobenzyl)-2-(2-furyl)-
pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]
pyrimidine)
SCH 58261 5-amino-7-(β-phenylethyl)-2-(2-furyl)pyra-
zolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine
SCH 63390 5-amino-7-(3-phenylpropyl)-2-(2-furyl)pyr-
azolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine
SCH 442416 5-amino-7-[3-(4-methoxyphenyl)propyl]-
2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo
[1,5-c]pyrimidine
PET positron emission tomography
MRS 1220 N-[9-chloro-2-(2-furanyl)[1,2,4]triazolo
[1,5-c]quinazolin-5-yl]benzene-acetamide
MRE3008-
F20
5-[[(4-Methoxyphenyl)amino]carbonyl]
amino-8-propyl-2-(2-furyl)-pyrazolo[4,3-e]
1,2,4-triazolo[1,5-c]pyrimidine
TM transmembrane domain
Introduction
In the last 10 years the pyrazolo-triazolo-pyrimidine nucleus
(1) represented an attractive key intermediate for obtaining
adenosine receptor antagonists due to its strong structural
correlation with the nonselective adenosine receptor antag-
onist CGS15943 (2)[ 1, 2] (Figure 1).
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(*)The great advantage of this nucleus with respect to the
reference compound (2) is related to a large number of
substitutions that could be done on this nucleus, such as in
positions N
7,N
8,N
5,C
9,o rC
2 opening kaleidoscopic
possibilities for different substituted heterocycles as adeno-
sine receptor antagonists. The aim of this review was to
briefly summarize the great efforts made on this class of
compounds, resulting in a complete structure–activity rela-
tionship (SAR) profile of the pyrazolo-triazolo-pyrimidine
family.
Substitutions at the N
7 and N
8 positions
The first example of adenosine receptor antagonists with
the pyrazolo-triazolo-pyrimidine nucleus was reported by
Gatta and coworkers [3], who proposed a compound named
8FB-PTP (3), which displayed potent binding to but no
selectivity versus A2A adenosine receptors (Figure 2).
Taking into account this experimental observation and
considering the limited number of compounds reported by
Gatta et al., our group decided to extensively investigate the
effect of substitutions on the pyrazole moiety. From earlier
studies, the importance of the free amino group at 5-
position and the effect of the substituent on the pyrazole
ring seems to be fundamental for both high affinity and
selectivity for the A2A adenosine receptor subtype. In
particular, substitutions at 7-position improve the selectivity
for the A2A adenosine receptor whereas the same substitu-
tions at 8-position increase the potency both at the A1 and
A2A receptors with low levels of selectivity as a conse-
quence, as indicated for the N
7-n-butyl (4)a n dt h eN
8-
n-butyl (5) derivatives [4, 5]( F i g u r e2).
An accurate investigation of the effect of the chain at the
N
7 position clearly demonstrated that the presence of an
aralkyl chain seems to be essential for both potency and
selectivity at the A2A adenosine receptors. In fact, two
selected compounds, named SCH 58261 (6) and SCH
63390 (7) proved to be the most potent and selective A2A
adenosine receptor antagonists ever reported, both in rat
and human models [5] (Figure 3).
Nevertheless, this class of compounds presents a
significant problem in relation to the poor water solubility,
which compromises the use of this compound as pharma-
cological tool. To overcome this problem, several polar
moieties on the side chain of the pyrazole nucleus have
been introduced. In particular, the introduction of a hydroxyl
functionat the para position of the phenyl ring of compounds
(6) and (7), as in one of the most potent and selective A2A
antagonist ZM241385 (4-[2-[[7-amino-2-(2-furyl) [1,2,4]-
triazolo[2,3-a] [1,3,5]triazin-5-yl]amino]ethyl]phenol) [6a],
led to derivatives (8) (5-amino-7-[β-(4-hydroxyphenyl)
ethyl]-2-(2-furyl)pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrim-
idine) and (9) (5-amino-7-[3-(4-hydroxyphenyl)propyl]-2-
(2-furyl)pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine),
which not only showed a better hydrophilic character but
also a significant increase of both affinity and selectivity
for the A2A adenosine receptor subtype, suggesting that
most probably, a hydrogen bond is involved in the receptor
recognition via this part of the ligand [6] (Figure 4).
To understand the nature of such a hypothetical
hydrogen bond, compound SCH 442416 (10) was synthe-
Figure 2 Structures and binding affinities of the first synthesized pyrazolo-triazolo-pyrimidines: effect of the substituent position [3, 5]
Figure 1 Structural similarities between pyrazolo-triazolo-pyrimi-
dines and reference compound CGS15943 [1]
184 Purinergic Signalling (2007) 3:183–193sized. This derivative showed even higher affinity and
selectivity for the A2A adenosine receptor, which makes it a
candidate as a tool for positron emission tomography (PET)
studies in its
11C-labeled form [7]. In addition, this
derivative confirms the role of a hydrogen bond via the
pyrazolo side chain.
However, the introduction of oxygenated groups could not
be considered sufficient to confer water solubility. For this
reason, carboxylic (11) and sulfonic (12) moieties were
introduced, which contributed highly to the water solubility,
in particular, the sulfonic moiety. However, in some cases, a
loss of affinity with respect to reference compounds (8, 9)
for the A2A adenosine receptor was the consequence. In
contrast, the introduction of an amino group at para position
of the phenyl ring in the side chain (13) gave better results
in terms of affinity and selectivity for the A2A adenosine
receptor subtype, but unfortunately, the water solubility was
not optimal for a possible therapeutic use. From these
advanced studies, it seemed very hard to find a useful
combination of affinity, selectivity, and acceptable charac-
teristics of bioavailability [8] (Figure 5).
The binding data for these compounds revealed another
relevant aspect relating to the N
7 and N
8 pattern of
substitutions (e.g., compounds 6 and 14) (see also Figure 3)
[5]. It is quite evident that the N
7 derivative (6) is totally
inactive at the human A2B and A3 receptors whereas the N
8
isomer (14) showed a slight affinity profile for these two
receptor subtypes.
Figure 3 First generation of
pyrazolo-triazolo-pyrimidines
as potent and selective A2A
adenosine receptor antagonists
[5, 6b, 8]
Figure 4 Hydrophilic pyrazolo-
triazolo-pyrimidines as A2A
adenosine receptor antagonists
[6b]
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mental role of space occupancy of the substitutions on the
pyrazole nucleus for recognition of the different receptor
subtypes, and it represented a staring point for further
studies.
Substitution at the N
5 position
These results described above led us to thoroughly
investigate this structure as a possible template for other
subtype selective ligands, in particular, versus the human
A3 and A2B adenosine receptors. Taking into account these
data and the fact that MRS 1220, (15)[ 9] was the most
potent but not highly selectivte A3 adenosine receptor
antagonist reported in the literature, and considering the
structural relation to CGS15943 (1) and the pyrazolo-
triazolo-pyrimidine core, we modified the N
5 position of
this nucleus in an attempt to obtain antagonists for the
human A3 adenosine receptor.
The planned modification was based on the introduction of a
phenylcarbamoyl chain (4-OMe or 3-Cl substituted) present
in a previously reported series of N
6 (substituted phenyl-
carbamoyl) adenosine-5’-uronamides, as A3 agonists, of
general formula (16), [4, 5], at the N
5 position of the
pyrazolo-triazolo-pyrimidine scaffold [10, 11] (Figure 6).
A preliminary study led to the discovery of compound
(5-[[(4-methoxyphenyl)amino]carbonyl]amino-8-ethyl-2-
(2-furyl)-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine
(17), which turned out to be the most potent and selective
human A3 adenosine receptor antagonist ever reported and
yet was totally inactive in a rat model [12].
This result represented the starting point for an intensive
investigation of this new class of human A3 adenosine
receptor antagonist. A classic SAR approach for studying
this new class of human A3 adenosine receptor antagonists
was performed. We found an interesting correlation
between the calculated molecular volume of pyrazolo[4,3-
e]1,2,4-triazolo[1,5-c]pyrimidine derivatives and their ex-
perimental Ki values. In fact, it was observed that the A3
Figure 5 Structures and
binding affinities of different
water-soluble pyrazolo-tria-
zolo-pyrimidines [8]
186 Purinergic Signalling (2007) 3:183–193affinities decrease with increasing molecular volume values
at the N
8 position. All these observations suggested that
small alkyl groups at the N
8 pyrazole nitrogen combined
with the N
5-(4-methoxy)phenylcarbamoyl substitution af-
ford the best compounds in terms of affinity and selectivity
at the human A3 adenosine receptors [13].
In particular, when the N
8-methyl and N
5-(4-methoxy)
phenylcarbamoyl substitutions were combined, the most
potent and selective human A3 adenosine antagonist (18)
was obtained [13]. A molecular modeling investigation,
reported in the next session/paragraph, was derived in order
to rationalize these experimental results. This study also
permitted the introduction of an allyl chain at the N
8
position that, after reduction with tritium, afforded a labeled
form named MRE3008-F20 (19), which was the first
antagonist radioligand utilized for studying the human A3
adenosine receptor, showing a KD value of 0.82 nM and a
Bmax of 297 fmol/mg protein (Figure 7)[ 14, 15].
As for the A2A antagonists, these derivatives also
showed very low water solubility, which limits their use
for therapeutic purpose. Considering that only the phenyl
ring is a suitable core for the introduction of polar
substituents, we investigated which position (ortho, meta,
para) and substituent (e.g., Br, SO3H, F, H, CH3,C F 3)
could be suitable to solve this problem while maintaining a
small substituents (methyl) at the N
8 position. The
molecular modeling study performed on the synthesized
compounds suggested that the steric factors at the ortho or
para position on the phenyl ring play a fundamental role
for affinity at the human A3 receptors, and a very rigid
steric control is present at the meta position. In fact,
compound (20) was found to be the best compound of the
series whereas derivative (21), which is completely water
soluble, showed a dramatic loss of potency and selectivity
[16] (Figure 8).
Figure 6 Rational design of the
human A3 adenosine receptor
antagonists
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stituents are not well tolerated on the phenyl ring (see
compounds 20 and 21), the bioisosteric replacement of the
phenyl ring with the 4-pyridyl moiety was performed, thus
providing higher water solubility while avoiding the steric
hindrance of a substituent at the para position, which seemed
to be responsible for the reduction of human A3 adenosine
receptor affinity. This approach led us to the discovery of the
most potent (pM range), selective (>10,000)—and most
importantly—water-soluble (15 mM) (22)h u m a nA 3 adeno-
sine receptor antagonist.
The high potency of this compound was confirmed by
functional assay. An analysis of the antagonism of agonist-
induced inhibition of cyclic adenosine monophosphate
(cAMP) production in Chinese hamster ovary (CHO) cells
expressing the human A3 receptor indicated a KB value of
0.20 nM for compound (22)[ 17]. In this case, the support of
molecular modeling was fundamental not only for the design
of this derivative but also for understanding why the
presence of an endocyclic nitrogen was capable of inducing
a significant increase of potency in binding interaction. In
fact, strong electrostatic interactions appeared to occur
between the positively charged pyridinium moiety of (22)
and the carbonyl oxygen atoms of Asn274 (N
+H⋯ OC
distance=2.5 Å) and Asn278 (N
+H⋯ OC distance=3.1 Å),
both located on transmembrane (TM)7, which could be
considered responsible for the increase in affinity
A quite similar approach was utilized for the improve-
ment of the affinity at human A2B adenosine receptors. In
fact, CGS15943 not only binds to human A3 receptors but
displays good affinity for the A2B subtype. Jacobson and
coworkers observed that the introduction of polar moieties,
such as γ-aminobutyryl amide (23), results in increased
potency at the A2B adenosine receptors but a complete lack
of selectivity versus the A1 and A2A subtypes. However, the
presence of apolar chains, such as the N
5-pyvaloyl (24)o r
the N
5-tert-butyloxycarbony derivative (25), displayed less
potency than derivative (23) at the A2B adenosine receptors
but an increased selectivity versus the other receptor
subtypes, indicating a preliminary SAR profile of this class
of compounds as A2B adenosine receptor antagonists
(Figure 9)[ 18].
Considering these data, we performed a similar approach
on the pyrazolo-triazolo-pyrimidines. We observed that the
N
5 unsubstituted derivatives (14, 26) possess high affinity
at the human A2B adenosine receptors but a complete lack
of selectivity. Instead, its substitution with a γ-amino-
Figure 8 Structures and binding affinities of the most interesting
compounds modified at the phenyl ring [16]
Figure 7 [
3H]-MRE3008-F20,
the first radioligand for the
human A3 adenosine receptor
[14, 15]
188 Purinergic Signalling (2007) 3:183–193butyryl amide (27) produces a decrease of affinity at the
A2B adenosine receptors but was found to be slightly
selective versus the A2A subtype [19] (Figure 10).
An improvement of this class of compounds was
achieved by an optimized pattern of substitutions at the
N
5 and N
8 positions. In fact, in parallel studies on human
A3 adenosine antagonists, we observed that replacement of
the phenylcarbamoyl moiety at the N
5 position with a
phenylacetyl group (e.g., compound 28) produces a
decrease in affinity at the human A3 adenosine receptor
affinity and a retention or improvement versus the A2B
subtype. In fact, a combination of a naphthyl acetyl moiety
at the N
5 position and a phenylpropyl group (characteristic
of A2A antagonists) at the N
8 position led to compound
(29), which was found to be quite potent and selective for
the A2B adenosine receptors [20] (Figure 11).
These results seem to suggest that bulky substituents at
both the N
5 and N
8 positions could lead to potent and
selective A2B adenosine receptor antagonists [20]. A
theoretical comparison of the putative TM binding motif
of compound (29) on both human A2B and human A3
receptors was able to elucidate these results, explaining
why such small modifications could significantly change
the biological profile of this class of compounds.
Molecular modeling
We recently developed a combined target-based and ligand-
based drug design approach to define a pharmacophore
model of human A3 receptor antagonists, in order to lead
the discovery and the structural refinement of new potent
and selective human A3 receptor antagonists. In particular,
we developed a rhodopsin-based model of the human A3
receptor to provide more accurate information about the
putative binding site of the pyrazolo-triazolo-pyrimidines
[16, 17, 20–24]. As already reported, this binding site for
A3 agonists and antagonists was located in the upper region
of the TM helical bundle of the receptor. The human A3
receptor model revealed a central pocket surrounded by
helices 1–7 and 5–6, as TM4 is not part of the cavity wall.
TMs 3, 5, 6, and 7 seem to be crucial for the recognition of
A3 receptor ligands, and particular care has been given to
the second extracellular loop (EL2). EL2, as for rhodopsin,
Figure 9 Structures and bind-
ing affinities of triazolo-quina-
zolines as A2B adenosine
receptor antagonists [18]
Figure 10 Structures and binding affinities of pyrazolo-triazolo-
pyrimidines as A2B adenosine receptor antagonists [19]
Figure 11 Structures and binding affinities of N
5 arylacetyl pyrazolo-
triazolo-pyrimidines as A2B adenosine receptor antagonists [20]
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recognition site and preventing access to the cavity from the
periplasm [25]. Docking studies, validated by site-directed
mutagenesis analysis, pointed out several residues in
transmembrane domains 3 and 5 and in the EL2 that seem
to be critical for ligand recognition, including His95,
Trp243, Ser247, Asn250, and Lys152 [23, 24, 26]. The
molecular docking study was carried out on more than 200
pyrazolo-triazolo-pyrimidine derivatives to recognize the
hypothetical binding motif of human A3 receptor antago-
nists and to define a target-based pharmacophore model.
Consequently, to generate a three-dimensional (3D)-driven
pharmacophore hypothesis, the docked low energy con-
formations of pyrazole-triazolo-pyrimidine were used as a
structural template. Therefore, we identified the hypothet-
ical binding site of these derivatives and proposed a “Y-
shaped” pharmacophore model [22]. Interestingly, all
derivatives share a common binding motif inside the TM
region of human A3 receptors: the pyrazole-triazolo-
pyrimidine moiety is surrounded by TMs 3, 5, 6, and 7,
with the furan ring and the N
8 substituents pointing toward
the EL2 and the carbamoyl moiety in the 5-position
oriented toward the intracellular environment. The Y-shape
binding motif is defined by a peculiar and highly conserved
binding mode: the furan ring is positioned between TM5
and TM3 whereas the N
8 substituents are surrounded by
TM2 and TM7.
Moreover, analyzing in detail the 3D pharmacophore
model, we identified five regions that seem to be crucial for
antagonists recognition. In particular, all pyrazole-triazolo-
pyrimidine derivatives present the carbamoyl moiety in the
5-position such that it is surrounded by two polar amino
a c i d s :H i s 9 5( T M 3 )a n dS e r 2 4 7( T M 6 ) .T h em a j o r
structural difference between the hypothetical binding sites
in adenosine receptor subtypes is that the A3 receptor does
not contain the histidine residue in TM6 common to all A1
(His251 in hA1) and A2 (His250 in hA2A) receptors. This
histidine has been shown to participate in both agonist and
antagonist binding to A2A receptors whereas in the A3
receptor, the histidine is replaced with a serine residue
(Ser247 in hA3)[ 27, 28]. The polar amino acids stabilize
interactions with the carbamoyl moiety, and consequently,
the carbamoyl phenyl ring is oriented in the middle of the
TM bundle (Figure 12).
In particular, 2.6 Å separate the N-H of His95 (TM3)
and the oxygen atom of the carbamoyl group, appropriately
oriented to form a H-bonding interaction. The side chain of
Ser247 (TM6) is within hydrogen-bonding distance of NH
of the carbamoyl group at 2.9 Å. The phenyl ring of the
carbamoyl moiety takes place in a receptor region that is
hydrophobic and characterized by three nonpolar amino
acids: Ile98 (TM3), Ile186 (TM5), and Leu244 (TM6). As a
consequence of this, polar substituents, such as a sulfonic
acid group at the para position of the phenyl ring, are not
very well tolerated [16]. Moreover, around this para
position, it seems that a steric control is present because
of the very limited empty space between TM5 and TM6. In
fact, there is a reduction in the affinity at the human A3
adenosine receptors of the N
5 phenyl ring derivatives
substituted at the para position [16, 17]. In the case of
meta substitutions, we observed a similar steric control
when the meta residues are larger than hydrogen: a
significant affinity reduction at the human A3 receptor is
due to the strong steric repulsion among the meta
substituents and amino acid side chains of TM6 and TM7.
In contrast, the residues at the ortho position seem to
occupy an empty region of the binding cavity.
Another important pharmacophore feature is located in a
highly conserved region delimited by Phe168 (EL2) and
Phe182 (TM5). There is a probable π–π interaction
between the furan ring of the pyrazole-triazolo-pyrimidine
and these two phenylalanine residues. In particular, the
amino acids corresponding to Leu90 (TM3) and Phe182 in
the human A2A receptor was found to be essential for the
binding of both agonists and antagonists [28]. Moreover,
the nonpolar amino acid Leu90, together with Leu246
(TM6) and Ile268 (TM7), delimited a peculiar hydrophobic
pocket where all the substituents at the N
8 position are
located, with a good tolerance for the hydrophobic ones.
However, in the presence of appropriate substituents,
hydrogen bonding can be established with two hydrophilic
Figure 12 General topology of the human A3 receptor model.
Reference compound 20 (colored in magenta) is docking inside the
transmembrane recognition site. Side chains of some amino acids
important for ligand recognition are highlighted
190 Purinergic Signalling (2007) 3:183–193amino acids, namely, Ser175 (EL2) and the His272 (TM7),
located on the border of this hydrophobic pocket. [13]
However, other aromatic rings, such as phenyl or thio-
phenyl, seem to be less well tolerated by the receptor-
binding pocket, probably due to their less favorable steric
complementaries [29].
Another strong hydrogen bonding interaction occurs
between Asn250 (TM6) and the triazolo ring of the
pyrazole-triazolo-pyrimidine moiety. The N-H of Asp250
and the N
4 of the triazolo ring group are, in fact, separated
by 2.5 Å and appropriately oriented to form an H-bonding
interaction. The two polar amino acids Thr94 (TM3) and
Ser97 (TM3) were shown to be important for the
coordination of agonist but not for antagonist binding at
A1 and A2A receptors, respectively. Therefore, no direct
interactions have been predicted between them and the
antagonist structure.
In parallel with the docking studies and the target-based
pharmacophore model generation, we derived a compara-
tive molecular field analysis (CoMFA) on the pyrazole-
triazolo-pyrimidine analogue binding data, as alternative
scoring function for the prediction of ligand-receptor-
binding affinity [22, 24]. The analysis was performed
considering the previous results of the docking approach.
The CoMFA approach consists of the computation of steric
and electrostatic field variables calculated at grid points
surrounding the whole molecule, followed by a partial least
squares (PLS) on these 3D structure descriptors and on the
biological activity. The PLS analysis, followed by cross-
validation, showed very good values of correlation,
meaning high predictivity power of the quantitative
structure activity relationship (QSAR) model. The CoMFA
results can be observed and analyzed as a contour plot and
regression plots. The contour plot consists of colored
polyhedra that describe the regions of space where the
steric and electrostatic fields are predicted to have an effect
on binding affinity. The yellow and the blue contours
correspond to regions of the field where increase steric bulk
and electronegative character is associated with a decrease
of receptor affinity. In particular, we observed that the
contour map displays a green polyhedron nearby the N
5-
carbamoyl moiety, suggesting enhanced A3 receptor affinity
if we introduce sterically bulky substituents in this position.
As already described, this steric-bulk-favorable region
nicely fits with the receptor region around the phenyl ring
of the carbamoyl moiety, characterized by the three
nonpolar amino acids Ile98(TM3), Ile187(TM5), and
Leu244(TM6). On the other side, we observed two red
polyhedra located around to N
8 substituents and to the N
5-
carbamoyl moiety, complementary to the polar amino acids
Ser175 (EL2), His95 (TM3), Ser247 (TM6), and His272
(TM7) present in this region in the A3-receptor-binding-site
model. Similarly, the blue polyhedron close to the N
5
phenyl ring is complementary to the nonpolar residues
Ile98 (TM3), Ile186 (TM5), Phe239 (TM6), and Leu244
(TM6) (Figure 13).
In Figure 13, we present the CoMFA contour plot of a
pyrazole-triazolo-pyrimidine derivative docked inside the
human A3-receptor-binding-site model. We can see that all
steric and electrostatic features are coherent with the SAR
previously described in the molecular docking analysis.
This combined approach between a very consolidated
target-based approach, such as molecular docking, and a
solid quantitative ligand-based methodology, such as
CoMFA, is very advantageous for the identification of
common structural features of pyrazolo-triazolo-pyrimi-
dines important for the affinity at the A3 receptor. We
have, in fact, had really good results in validation of this
Figure 13 Side view of the 20-A3 complex model. The side chains of
some crucial important residues in proximity (≤5 Å) to the docked
pyrazolo-triazolo-pyrimidine molecule are highlighted and labeled:
Leu90 (TM3), His 95 (TM3); Phe182 (TM5), Ile186 (TM5); Trp243
(TM6); Ser247 (TM6), Asn250 (TM6), Ser271 (TM7), His272 (TM7),
Ser275 (TM7). The steric and the electrostatic contour plots, obtained
from the comparative molecular field analysis (CoMFA), are included
into ligand binding cavity. The yellow and the blue polyhedra
correspond to regions of the field that are predicted to decrease the
A3 receptor affinity whereas the green and the red regions are
predicted to increase binding affinity
Figure 14 Structures and binding profile of C
2 and C
9 substituted
pyrazolo-triazolo-pyrimidines [30]
Purinergic Signalling (2007) 3:183–193 191combined approach, predicting with high precision the
binding affinity values of new derivatives with a different
spectrum of affinity at the human A3 receptor.[22, 24]
Substitutions at the C
2 and C
9 positions
Very recently, a number of pyrazolo-triazolo-pyrimidines
with classic substituents at N
7 and N
5 positions have been
modified at the C
2 or C
9 positions. In general, it has been
observed that the introduction of a substituent on the C
9
position (e.g., SCH3, NHCH2CH3) led to retention of a
receptor affinity but a complete loss of selectivity between
different receptor subtypes. Indeed, substitution of the furan
ring with phenyl or alkoxyphenyl rings led to a loss of
affinity at A2A,A 2B, and A3 adenosine receptors only. At
the A1 receptor, a high nanomolar affinity is still present.
Also, the introduction of polar substituents (by Mannich
reaction) on the furan ring led to complete inactivity. Som
examples (30, 31) are depicted in Figure 14.
These data clearly indicate that position 9 plays a role for
selectivity whereas the presence of an unsubstituted furan
ring at the C
2 position plays a fundamental role in ligand-
receptor recognition [30].
Concluding remarks
All the work performed on the pyrazolo-triazolo-pyrimidine
nucleus resulted in potent and selective ligands for A2A,
A2B, and A3 adenosine receptor subtypes whereas for the
A1 subtype, potency was achieved but selectivity was very
poor. All these experimental observations resulted in a quite
significant SAR profile of this nucleus for the adenosine
receptor subtypes. In addition, in the case of A3 adenosine
receptor, all these studies allowed development of a receptor-
based pharmacophore model with high levels of predictivity
for newly designed compounds, as recently reported.
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